Melanoma - Pipeline Review, H2 2015

Date: December 31, 2015
Pages: 1508
Price:
US$ 2,500.00 US$ 2,125.00
Offer valid until December 31, 2016!
License [?]:
Publisher: Global Markets Direct
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: M94D1D30D60EN
Leaflet:

Download PDF Leaflet

Melanoma - Pipeline Review, H2 2015

SUMMARY

Global Markets Direct’s, ‘Melanoma - Pipeline Review, H2 2015’, provides an overview of the Melanoma’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Melanoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Melanoma and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

SCOPE
  • The report provides a snapshot of the global therapeutic landscape of Melanoma
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Melanoma and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Melanoma products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Melanoma pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products
REASONS TO BUY
  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Melanoma
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Melanoma pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Introduction
Melanoma Overview
Therapeutics Development
Melanoma - Therapeutics under Development by Companies
Melanoma - Therapeutics under Investigation by Universities/Institutes
Melanoma - Pipeline Products Glance
Melanoma - Products under Development by Companies
Melanoma - Products under Investigation by Universities/Institutes
Melanoma - Companies Involved in Therapeutics Development
Melanoma - Therapeutics Assessment
Drug Profiles
Melanoma - Recent Pipeline Updates 1084
Melanoma - Dormant Projects 1407
Melanoma - Discontinued Products 1442
Melanoma - Product Development Milestones 1446
Appendix 1456

LIST OF TABLES

Number of Products under Development for Melanoma, H2 2015
Number of Products under Development for Melanoma - Comparative Analysis, H2 2015
Number of Products under Development by Companies, H2 2015
Number of Products under Development by Companies, H2 2015 (Contd..1)
Number of Products under Development by Companies, H2 2015 (Contd..2)
Number of Products under Development by Companies, H2 2015 (Contd..3)
Number of Products under Development by Companies, H2 2015 (Contd..4)
Number of Products under Development by Companies, H2 2015 (Contd..5)
Number of Products under Development by Companies, H2 2015 (Contd..6)
Number of Products under Development by Companies, H2 2015 (Contd..7)
Number of Products under Development by Companies, H2 2015 (Contd..8)
Number of Products under Development by Companies, H2 2015 (Contd..9)
Number of Products under Development by Companies, H2 2015 (Contd..10)
Number of Products under Development by Companies, H2 2015 (Contd..11)
Number of Products under Development by Companies, H2 2015 (Contd..12)
Number of Products under Development by Companies, H2 2015 (Contd..13)
Number of Products under Development by Companies, H2 2015 (Contd..14)
Number of Products under Development by Companies, H2 2015 (Contd..15)
Number of Products under Development by Companies, H2 2015 (Contd..16)
Number of Products under Development by Companies, H2 2015 (Contd..17)
Number of Products under Development by Companies, H2 2015 (Contd..18)
Number of Products under Development by Companies, H2 2015 (Contd..19)
Number of Products under Investigation by Universities/Institutes, H2 2015
Number of Products under Investigation by Universities/Institutes, H2 2015 (Contd..1)
Number of Products under Investigation by Universities/Institutes, H2 2015 (Contd..2)
Number of Products under Investigation by Universities/Institutes, H2 2015 (Contd..3)
Comparative Analysis by Late Stage Development, H2 2015
Comparative Analysis by Clinical Stage Development, H2 2015
Comparative Analysis by Early Stage Development, H2 2015
Products under Development by Companies, H2 2015
Products under Development by Companies, H2 2015 (Contd..1)
Products under Development by Companies, H2 2015 (Contd..2)
Products under Development by Companies, H2 2015 (Contd..3)
Products under Development by Companies, H2 2015 (Contd..4)
Products under Development by Companies, H2 2015 (Contd..5)
Products under Development by Companies, H2 2015 (Contd..6)
Products under Development by Companies, H2 2015 (Contd..7)
Products under Development by Companies, H2 2015 (Contd..8)
Products under Development by Companies, H2 2015 (Contd..9)
Products under Development by Companies, H2 2015 (Contd..10)
Products under Development by Companies, H2 2015 (Contd..11)
Products under Development by Companies, H2 2015 (Contd..12)
Products under Development by Companies, H2 2015 (Contd..13)
Products under Development by Companies, H2 2015 (Contd..14)
Products under Development by Companies, H2 2015 (Contd..15)
Products under Development by Companies, H2 2015 (Contd..16)
Products under Development by Companies, H2 2015 (Contd..17)
Products under Development by Companies, H2 2015 (Contd..18)
Products under Development by Companies, H2 2015 (Contd..19)
Products under Development by Companies, H2 2015 (Contd..20)
Products under Development by Companies, H2 2015 (Contd..21)
Products under Development by Companies, H2 2015 (Contd..22)
Products under Development by Companies, H2 2015 (Contd..23)
Products under Development by Companies, H2 2015 (Contd..24)
Products under Development by Companies, H2 2015 (Contd..25)
Products under Development by Companies, H2 2015 (Contd..26)
Products under Investigation by Universities/Institutes, H2 2015
Products under Investigation by Universities/Institutes, H2 2015 (Contd..1)
Products under Investigation by Universities/Institutes, H2 2015 (Contd..2)
Products under Investigation by Universities/Institutes, H2 2015 (Contd..3)
Products under Investigation by Universities/Institutes, H2 2015 (Contd..4)
Products under Investigation by Universities/Institutes, H2 2015 (Contd..5)
Melanoma - Pipeline by AB Science SA, H2 2015
Melanoma - Pipeline by AbbVie Inc., H2 2015
Melanoma - Pipeline by ACF Pharmaceuticals, LLC, H2 2015
Melanoma - Pipeline by Adamis Pharmaceuticals Corporation, H2 2015
Melanoma - Pipeline by Adaptimmune Limited, H2 2015
Melanoma - Pipeline by Aduro BioTech, Inc., H2 2015
Melanoma - Pipeline by Advaxis, Inc., H2 2015
Melanoma - Pipeline by Aeterna Zentaris Inc., H2 2015
Melanoma - Pipeline by Affichem SA, H2 2015
Melanoma - Pipeline by Agalimmune Ltd, H2 2015
Melanoma - Pipeline by Agenus, Inc., H2 2015
Melanoma - Pipeline by Agilvax, Inc., H2 2015
Melanoma - Pipeline by AGV Discovery, SAS, H2 2015
Melanoma - Pipeline by AIMM Therapeutics B.V., H2 2015
Melanoma - Pipeline by Alethia Biotherapeutics Inc., H2 2015
Melanoma - Pipeline by Altor BioScience Corporation, H2 2015
Melanoma - Pipeline by Amgen Inc., H2 2015
Melanoma - Pipeline by Anavex Life Sciences Corp., H2 2015
Melanoma - Pipeline by Antigen Express, Inc., H2 2015
Melanoma - Pipeline by APEIRON Biologics AG, H2 2015
Melanoma - Pipeline by Aphios Corporation, H2 2015
Melanoma - Pipeline by APO-T B.V., H2 2015
Melanoma - Pipeline by Aposense Ltd., H2 2015
Melanoma - Pipeline by Applied Immune Technologies Ltd, H2 2015
Melanoma - Pipeline by Aptose Biosciences Inc., H2 2015
Melanoma - Pipeline by Arisaph Pharmaceuticals, Inc., H2 2015
Melanoma - Pipeline by Array BioPharma Inc., H2 2015
Melanoma - Pipeline by Arrowhead Research Corporation, H2 2015
Melanoma - Pipeline by Astex Pharmaceuticals, Inc., H2 2015
Melanoma - Pipeline by AstraZeneca Plc, H2 2015
Melanoma - Pipeline by Aurigene Discovery Technologies Limited, H2 2015
Melanoma - Pipeline by Axelar AB, H2 2015
Melanoma - Pipeline by Azaya Therapeutics, Inc., H2 2015
Melanoma - Pipeline by Basilea Pharmaceutica AG, H2 2015
Melanoma - Pipeline by Bayer AG, H2 2015
Melanoma - Pipeline by BeiGene(Beijing) Co.,Ltd, H2 2015
Melanoma - Pipeline by Bellicum Pharmaceuticals, Inc., H2 2015
Melanoma - Pipeline by Bio-Cancer Treatment International Limited, H2 2015
Melanoma - Pipeline by Biogenomics Limited, H2 2015
Melanoma - Pipeline by BioLineRx, Ltd., H2 2015
Melanoma - Pipeline by Bioncotech Therapeutics S.L., H2 2015
Melanoma - Pipeline by Bionomics Limited, H2 2015
Melanoma - Pipeline by BioNTech AG, H2 2015
Melanoma - Pipeline by Bioo Therapeutics, H2 2015
Melanoma - Pipeline by Biovista Inc., H2 2015
Melanoma - Pipeline by Boehringer Ingelheim GmbH, H2 2015
Melanoma - Pipeline by Boston Biomedical, Inc., H2 2015
Melanoma - Pipeline by Bristol-Myers Squibb Company, H2 2015
Melanoma - Pipeline by Caladrius Biosciences, Inc. , H2 2015
Melanoma - Pipeline by Can-Fite BioPharma Ltd., H2 2015
Melanoma - Pipeline by Cantargia AB, H2 2015
Melanoma - Pipeline by cCAM Biotherapeutics Ltd., H2 2015
Melanoma - Pipeline by CCRP Therapeutics GmbH, H2 2015
Melanoma - Pipeline by Cellceutix Corporation, H2 2015
Melanoma - Pipeline by Celldex Therapeutics, Inc., H2 2015
Melanoma - Pipeline by Celyad SA, H2 2015
Melanoma - Pipeline by Champions Oncology, Inc., H2 2015
Melanoma - Pipeline by Cipher Pharmaceuticals Inc., H2 2015
Melanoma - Pipeline by Cornerstone Pharmaceuticals, Inc., H2 2015
Melanoma - Pipeline by Cytune Pharma SAS, H2 2015
Melanoma - Pipeline by CyTuVax B.V., H2 2015
Melanoma - Pipeline by CZ BioMed Corp, H2 2015
Melanoma - Pipeline by Daiichi Sankyo Company, Limited, H2 2015
Melanoma - Pipeline by Deciphera Pharmaceuticals, LLC, H2 2015
Melanoma - Pipeline by Delcath Systems, Inc., H2 2015
Melanoma - Pipeline by DermaXon, LLC, H2 2015
Melanoma - Pipeline by Dicerna Pharmaceuticals, Inc., H2 2015
Melanoma - Pipeline by Digna Biotech, S.L., H2 2015
Melanoma - Pipeline by DNA Therapeutics S.A., H2 2015
Melanoma - Pipeline by DormaTarg, Inc., H2 2015
Melanoma - Pipeline by Dynavax Technologies Corporation, H2 2015
Melanoma - Pipeline by EcoBiotics Limited, H2 2015
Melanoma - Pipeline by Egenix, Inc., H2 2015
Melanoma - Pipeline by Eisai Co., Ltd., H2 2015
Melanoma - Pipeline by Eli Lilly and Company, H2 2015
Melanoma - Pipeline by Ensol Biosciences Inc., H2 2015
Melanoma - Pipeline by EntreChem, S.L., H2 2015
Melanoma - Pipeline by Erytech Pharma SA, H2 2015
Melanoma - Pipeline by F. Hoffmann-La Roche Ltd., H2 2015
Melanoma - Pipeline by FAES Farma SA, H2 2015
Melanoma - Pipeline by FirstString Research, Inc., H2 2015
Melanoma - Pipeline by Five Prime Therapeutics, Inc., H2 2015
Melanoma - Pipeline by Formune S.L., H2 2015
Melanoma - Pipeline by Galapagos NV, H2 2015
Melanoma - Pipeline by Galectin Therapeutics, Inc., H2 2015
Melanoma - Pipeline by Galileo Research s.r.l., H2 2015
Melanoma - Pipeline by Genelux Corporation, H2 2015
Melanoma - Pipeline by Genzyme Corporation, H2 2015
Melanoma - Pipeline by GlaxoSmithKline Plc, H2 2015
Melanoma - Pipeline by Gradalis Inc., H2 2015
Melanoma - Pipeline by Hadasit Medical Research Services & Development Ltd, H2 2015
Melanoma - Pipeline by Hanmi Pharmaceuticals, Co. Ltd., H2 2015
Melanoma - Pipeline by HEC Pharm Co., Ltd., H2 2015
Melanoma - Pipeline by Histogen, Inc., H2 2015
Melanoma - Pipeline by Horizon Pharma Plc, H2 2015
Melanoma - Pipeline by Idera Pharmaceuticals, Inc., H2 2015
Melanoma - Pipeline by Ignyta, Inc., H2 2015
Melanoma - Pipeline by Immodulon Therapeutics Ltd., H2 2015
Melanoma - Pipeline by Immune Design Corp., H2 2015
Melanoma - Pipeline by Immune Response BioPharma, Inc., H2 2015
Melanoma - Pipeline by ImmunGene, Inc., H2 2015
Melanoma - Pipeline by ImmunNovative Developments SL, H2 2015
Melanoma - Pipeline by Immunocore Limited, H2 2015
Melanoma - Pipeline by ImmunoFrontier, Inc., H2 2015
Melanoma - Pipeline by ImmunoGen, Inc., H2 2015
Melanoma - Pipeline by Immunomic Therapeutics, Inc., H2 2015
Melanoma - Pipeline by Immunophotonics Inc, H2 2015
Melanoma - Pipeline by ImmuRx, Inc., H2 2015
Melanoma - Pipeline by IMPACT Therapeutics, Inc., H2 2015
Melanoma - Pipeline by Imugene Limited, H2 2015
Melanoma - Pipeline by Incyte Corporation, H2 2015
Melanoma - Pipeline by Inovio Pharmaceuticals, Inc., H2 2015

LIST OF FIGURES

Number of Products under Development for Melanoma, H2 2015
Number of Products under Development for Melanoma - Comparative Analysis, H2 2015
Number of Products under Development by Companies, H2 2015
Number of Products under Investigation by Universities/Institutes, H2 2015
Comparative Analysis by Late Stage Development, H2 2015
Comparative Analysis by Clinical Stage Development, H2 2015
Comparative Analysis by Early Stage Products, H2 2015
Assessment by Monotherapy Products, H2 2015
Assessment by Combination Products, H2 2015
Number of Products by Top 10 Targets, H2 2015
Number of Products by Stage and Top 10 Targets, H2 2015
Number of Products by Top 10 Mechanism of Actions, H2 2015
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2015
Number of Products by Top 10 Routes of Administration, H2 2015
Number of Products by Stage and Top 10 Routes of Administration, H2 2015
Number of Products by Top 10 Molecule Types, H2 2015
Number of Products by Stage and Top 10 Molecule Types, H2 2015

COMPANIES MENTIONED

AB Science SA
AbbVie Inc.
ACF Pharmaceuticals, LLC
Adamis Pharmaceuticals Corporation
Adaptimmune Limited
Aduro BioTech, Inc.
Advaxis, Inc.
Aeterna Zentaris Inc.
Affichem SA
Agalimmune Ltd
Agenus, Inc.
Agilvax, Inc.
AGV Discovery, SAS
AIMM Therapeutics B.V.
Alethia Biotherapeutics Inc.
Altor BioScience Corporation
Amgen Inc.
Anavex Life Sciences Corp.
Antigen Express, Inc.
APEIRON Biologics AG
Aphios Corporation
APO-T B.V.
Aposense Ltd.
Applied Immune Technologies Ltd
Aptose Biosciences Inc.
Arisaph Pharmaceuticals, Inc.
Array BioPharma Inc.
Arrowhead Research Corporation
Astex Pharmaceuticals, Inc.
AstraZeneca Plc
Aurigene Discovery Technologies Limited
Axelar AB
Azaya Therapeutics, Inc.
Basilea Pharmaceutica AG
Bayer AG
BeiGene(Beijing) Co.,Ltd
Bellicum Pharmaceuticals, Inc.
Bio-Cancer Treatment International Limited
Biogenomics Limited
BioLineRx, Ltd.
Bioncotech Therapeutics S.L.
Bionomics Limited
BioNTech AG
Bioo Therapeutics
Biovista Inc.
Boehringer Ingelheim GmbH
Boston Biomedical, Inc.
Bristol-Myers Squibb Company
Caladrius Biosciences, Inc.
Can-Fite BioPharma Ltd.
Cantargia AB
cCAM Biotherapeutics Ltd.
CCRP Therapeutics GmbH
Cellceutix Corporation
Celldex Therapeutics, Inc.
Celyad SA
Champions Oncology, Inc.
Cipher Pharmaceuticals Inc.
Cornerstone Pharmaceuticals, Inc.
Cytune Pharma SAS
CyTuVax B.V.
CZ BioMed Corp
Daiichi Sankyo Company, Limited
Deciphera Pharmaceuticals, LLC
Delcath Systems, Inc.
DermaXon, LLC
Dicerna Pharmaceuticals, Inc.
Digna Biotech, S.L.
DNA Therapeutics S.A.
DormaTarg, Inc.
Dynavax Technologies Corporation
EcoBiotics Limited
Egenix, Inc.
Eisai Co., Ltd.
Eli Lilly and Company
Ensol Biosciences Inc.
EntreChem, S.L.
Erytech Pharma SA
F. Hoffmann-La Roche Ltd.
FAES Farma SA
FirstString Research, Inc.
Five Prime Therapeutics, Inc.
Formune S.L.
Galapagos NV
Galectin Therapeutics, Inc.
Galileo Research s.r.l.
Genelux Corporation
Genzyme Corporation
GlaxoSmithKline Plc
Gradalis Inc.
Hadasit Medical Research Services & Development Ltd
Hanmi Pharmaceuticals, Co. Ltd.
HEC Pharm Co., Ltd.
Histogen, Inc.
Horizon Pharma Plc
Idera Pharmaceuticals, Inc.
Ignyta, Inc.
Immodulon Therapeutics Ltd.
Immune Design Corp.
Immune Response BioPharma, Inc.
ImmunGene, Inc.
ImmunNovative Developments SL
Immunocore Limited
ImmunoFrontier, Inc.
ImmunoGen, Inc.
Immunomic Therapeutics, Inc.
Immunophotonics Inc
ImmuRx, Inc.
IMPACT Therapeutics, Inc.
Imugene Limited
Incyte Corporation
Inovio Pharmaceuticals, Inc.
InteRNA Technologies B.V.
IO Biotech ApS
KAEL-GemVax Co., Ltd.
KaloBios Pharmaceuticals, Inc.
Kancera AB
Karyopharm Therapeutics, Inc.
Kite Pharma, Inc.
Kolltan Pharmaceuticals, Inc.
Kura Oncology, Inc.
Laboratoires Pierre Fabre SA
Lentigen Technology, Inc.
Life Science Pharmaceuticals, Incorporated
Lindis Biotech GmbH
Lipotek Pty Ltd.
Loxo Oncology, Inc.
Luitpold Pharmaceuticals, Inc.
Lytix Biopharma AS
MacroGenics, Inc.
Magnus Life Science
MediaPharma s.r.l.
MedImmune, LLC
Medivation, Inc.
MELEMA Pharma GmbH
Memgen, LLC.
Merck & Co., Inc.
Merck KGaA
Millennium Pharmaceuticals, Inc.
Mirna Therapeutics, Inc.
Molecular Templates Inc.
Mologen AG
Morphotek, Inc.
MSM Protein Technologies, Inc.
Multimmune GmbH
NantKwest, Inc.
Nektar Therapeutics
Nerviano Medical Sciences S.r.l.
Neumedicines Inc.
NewLink Genetics Corporation
NormOxys, Inc.
Northwest Biotherapeutics, Inc.
Novartis AG
Novogen Limited
Omeros Corporation
Oncology Research International Limited
Oncolytics Biotech Inc.
OncoNOx ApS
OncoSec Medical Inc.
Oncovir, Inc.
Ono Pharmaceutical Co., Ltd.
OPKO Health, Inc.
Pacific Northwest Biotechnology, LLC
Panacela Labs, Inc.
Patrys Limited
PepTx, Inc.
Peregrine Pharmaceuticals, Inc.
Pfizer Inc.
Pharminox Limited
Pharmis Biofarmaceutica, Lda.
Philogen S.p.A.
PinCell srl
Pivotal BioSciences, Inc.
Plexxikon Inc.
Polaris Pharmaceuticals, Inc.
Polyphor Ltd.
Prima BioMed Ltd.
Provectus Biopharmaceuticals, Inc.
Provenance Biopharmaceuticals Corp.
Qu Biologics Inc.
Reata Pharmaceuticals, Inc.
Recepta Biopharma S.A.
Recombio S.L
Rexahn Pharmaceuticals, Inc.
Rigontec GmbH
RXi Pharmaceuticals Corporation
Sapvax
SATT Nord
Scancell Holdings Plc
Sillajen Biotherapeutics
SK Biopharmaceuticals Co., Ltd.
Sorrento Therapeutics, Inc.
Spectrum Pharmaceuticals, Inc.
Sumitomo Dainippon Pharma Co., Ltd.
Summit Therapeutics Plc
Sun Pharma Advanced Research Company Ltd.
Susavion Biosciences, Inc.
Sutro Biopharma, Inc.
SuviCa Inc.
Syndax Pharmaceuticals, Inc.
Synta Pharmaceuticals Corp.
Taiga Biotechnologies, Inc.
Taiho Pharmaceutical Co., Ltd.
Takara Bio Inc.
Takeda Pharmaceutical Company Limited
Takis S.r.l.
Targovax AS
TC BioPharm Limited
Teva Pharmaceutical Industries Limited
Theravectys SA
TheRyte Limited
Tikcro Technologies, Ltd.
Tocagen Inc.
TREAT U, S.A.
TVAX Biomedical, Inc.
TyrNovo Ltd.
Ultimovacs AS
Vaccibody AS
Viralytics Ltd.
ViraTherapeutics GmbH
Virocan Therapeutics Private Limited
Virttu Biologics Limited
Welichem Biotech Inc.
WntResearch AB
ZIOPHARM Oncology, Inc.
Skip to top


Uveal Melanoma - Pipeline Review, H2 2016 US$ 2,000.00 Sep, 2016 · 108 pages
Uveal Melanoma - Pipeline Review, H1 2016 US$ 1,700.00 Apr, 2016 · 115 pages
Metastatic Uveal Melanoma - Pipeline Review, H1 2014 US$ 1,500.00 May, 2014 · 59 pages
Metastatic Uveal Melanoma - Pipeline Review, H2 2014 US$ 1,500.00 Oct, 2014 · 58 pages
Melanoma - Pipeline Review, 2015 US$ 3,200.00 Oct, 2015 · 86 pages

Ask Your Question

Melanoma - Pipeline Review, H2 2015
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: